{'fraction_non_alphanumeric': 0.01417004048582996, 'fraction_numerical': 0.0, 'mean_word_length': 4.963855421686747, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.

Sunitinib is a tyrosine kinase inhibitor with a low toxicity profile and proven activity against metastatic renal cell carcinoma (mRCC). However, there is very limited data on the effect of sunitinib on end stage renal disease owing to mRCC. We report our experience with the use of sunitinib in a patient with mRCC and end stage renal disease undergoing hemodialysis.